好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Phencyclidine Causing Opsoclonus and Myoclonus in a Four-month-old
Child Neurology and Developmental Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
8-007
To report a case of phencyclidine intoxication causing opsoclonus and myoclonus in an infant. 
Saccadic intrusions, when seen in pediatric patients, raise a concern for a possible paraneoplastic syndrome. Specifically, opsoclonus, with and without myoclonus, raises a concern for neuroblastoma. We report a case of opsoclonus and myoclonus in an infant, whose evaluation for neuroblastoma was negative, but who was found to have a positive urine comprehensive drug profile for phencyclidine. Opsoclonus can be rarely seen with PCP intoxication, and this was the presumed diagnosis in this patient, whose opsoclonus and myoclonus resolved over the course of hospitalization. 
NA

A healthy 4-month-old girl presented to the emergency department with symptoms of vomiting and diarrhea. During physical evaluation, patient’s mother shared that she recently started having chaotic eye movements. She also had been having jerking movements of her arms and legs periodically. A video was uploaded and reviewed by the neurology team, who was concerned that the movements appeared to be consistent with opsoclonus. She was admitted for further evaluation. 

Upon evaluation by both neurology and ophthalmology, there was agreement that movements were consistent with opsoclonus and myoclonus. Patient also was thought to have a distended abdomen. An ultrasound of the abdomen found no abdominal mass. MRI of brain, spine, chest and abdomen were also unrevealing.  

Meanwhile, the initial urine drug screen was positive for phencyclidine (PCP). Toxicology was consulted and initially suggested that this could be a false positive result. Ultimately, the comprehensive urine drug profile confirmed PCP in two separate samples of urine. As these results returned, patient’s opsoclonus and myoclonus gradually improved until they resolved by day 4 of hospitalization. Family later admitted to presence of PCP in the home. 

Our patient followed up with neurology six months after discharge, with normal development and no noticeable sequelae.  

NA
Authors/Disclosures
David S. Oleson, MD (UT Southwestern Medical Center)
PRESENTER
Dr. Oleson has nothing to disclose.
Michael M. Dowling, MD, PhD, FAAN Dr. Dowling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson and Johnson. Dr. Dowling has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NHLBI. The institution of Dr. Dowling has received research support from NIH.